Targeted gene silencing using RGD-labeled chitosan nanoparticles. - Wikidata - awgldk - TriplyDB

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

http://www.wikidata.org/entity/Q34031859

about

Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment Magnetic Nanoparticles in Cancer Theranostics Nanotechnology: Future of Oncotherapy Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics Nanotechnology in cancer therapy microRNA Therapeutics in Cancer - An Emerging Concept Preclinical and clinical development of siRNA-based therapeutics The ZNF304-integrin axis protects against anoikis in cancer Convergence of nanotechnology and cancer prevention: are we there yet?Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.Hematogenous metastasis of ovarian cancer: rethinking mode of spread.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications Functional roles of Src and Fgr in ovarian carcinoma.Dopamine blocks stress-mediated ovarian carcinoma growth.Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.MS-Monitored Conjugation of Poly(ethylene glycol) Monomethacrylate to RGD Peptides Improved tumor targeting of polymer-based nanovesicles using polymer-lipid blends In vivo sustained release of siRNA from solid lipid nanoparticles.RNA therapeutics targeting osteoclast-mediated excessive bone resorption.Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.Nanog signaling in cancer promotes stem-like phenotype and immune evasion Focal adhesion kinase is a phospho-regulated repressor of Rac and proliferation in human endothelial cells.Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.siRNA-mediated silencing of integrin β3 expression inhibits the metastatic potential of B16 melanoma cells.Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex Targeted polymeric therapeutic nanoparticles: design, development and clinical translation A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.New aspects of gene-silencing for the treatment of cardiovascular diseases Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes.In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.Tumour angiogenesis regulation by the miR-200 family.

P2860

Q26769963-4145B84E-4839-48EE-AD6A-276FA976B7FE Q26784379-CE94930F-AAAA-4E5B-AC66-78F8C71E73DB Q26801067-0A414231-6942-4651-A5BC-ACDB78734307 Q26823789-A8FF8C11-D61B-42E5-B639-7324277D3F60 Q27023013-2DB0015D-5213-43B0-8A4C-3702958189B2 Q28068855-899D0E6B-8A65-4224-9CDF-5AF16F80A39D Q28085290-375AA1C8-8153-4C49-B262-A4D6CB91F542 Q28115264-FD74F4B7-1674-4336-A882-4AC5A8D18D84 Q28386699-F5AC0DF3-24C1-4557-BEEE-8A36116FF03B Q28485257-A3DE32A5-3476-432E-B2C9-F0DDD087CF10 Q30421664-A0299FE9-B922-4002-BC90-E2810DAB4F17 Q30565636-F66785BA-15BC-430E-879A-C79DDA8892D8 Q33681168-675C6162-A61F-418F-A060-A8344068F905 Q33908024-F0CEC16E-D750-4FBF-A732-213F2126E044 Q33935474-FB9E94A2-84AC-4992-9BFE-DFEBDFD50E06 Q34165321-1CBAC806-A618-4358-BA58-73C1EF6C0CA8 Q34259986-F22A82CE-9ADF-49AD-86F8-9E9FA0327BCB Q34796603-569DBC40-82F9-45C5-B1E4-F2B642E943A4 Q35023940-4C929AFF-43C5-4CD6-871C-8EF650989E76 Q35196364-E4128A0B-3B45-4A01-AC17-00C210C41034 Q35197346-78B9AB78-593A-4E0E-B10F-74C04DFC6C1E Q35399928-DA203E53-8B85-4A04-841E-9DF496E57688 Q35635763-72C64880-A360-42EE-8BD6-F817C1347AA1 Q35800463-1DF70C89-CB14-455F-B5AB-8B3B20671E29 Q35871717-19D90709-788D-4EBA-9738-FA4399B2F5FA Q36357895-B4E9A199-C0B3-4325-AE3D-1F2BEC8876A0 Q36425657-97CD31BF-152A-4821-8ADC-B399E699AFEC Q36510958-73FF2CA8-3D2F-49D4-913E-84E390CE41F7 Q36557246-6ECE820C-9B2F-4165-81FC-80D47784F2DA Q36578825-160166D2-B02A-419F-982B-58F566E04E0F Q36589179-90A74733-BDE4-4CA7-A614-EFAD9EE8A343 Q36642289-FACB9CE5-47EE-4084-BB31-B33B811E4DD4 Q36776863-32815A8D-135C-4C80-A168-275B1B04E12B Q36934007-B39B3872-49D5-4F86-9ABA-16BFEAB1BA14 Q37094321-2FFF6873-9ED0-4459-8F5B-53A56CBE989C Q37277425-39835716-BE94-4D28-876D-F3E69822A739 Q37370429-DAD02F91-D173-4217-A9E8-3E426E62A8C1 Q37465136-A6A0B420-7CC2-49BE-A158-6AB807088B30 Q37472110-AB7A4DF9-B38F-4A8F-8B08-FBA6DC007EBD Q37523569-2A20A585-392B-4679-AC39-63891C9E2FE3

P2860

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

http://www.wikidata.org/entity/Q34031859

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@ast

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@en

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@nl

type

label

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@ast

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@en

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@nl

prefLabel

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@ast

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@en

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@nl

P1433

Q34031859-121633C3-7A4C-4659-816B-664C4689A18A

P1476

Q34031859-ABD47672-8AFC-4DAB-9D69-77D83B24F866

P2093

Q34031859-1938DDB7-D768-4EB3-9DD6-14F7427DDF93

Q34031859-226037C2-2AD4-4659-8222-43F510F7E48B

Q34031859-35B134AC-F295-458E-A0EC-0CC238E572E6

Q34031859-3ADA9A78-24E6-4EEA-AB38-2238DC27B363

Q34031859-4553F515-0107-44D4-B955-127C3E7B4B4C

Q34031859-78B662A1-E105-4CE3-BE98-E014D45FE89C

Q34031859-801FF3FB-7F79-451B-A4BC-A9491C0D9439

Q34031859-959F6C14-58B1-44C9-911F-4876D906B000

Q34031859-ABDF8CB6-32E6-4B6E-9A2D-F1EB694D61C8

Q34031859-BAA2C433-608D-4028-8FBD-188B64ED1677

P2860

Q34031859-01CD6B10-10FB-4597-9D70-87D41E7D63BE

Q34031859-039863E1-E23E-467A-B805-3FB8C840E106

Q34031859-04C60A4E-B72A-41FA-9F2F-F9A0357574A3

Q34031859-057C11A4-59B1-4121-A609-9A1758E72A06

Q34031859-1139B5E9-4F7E-42E9-861F-5D1F8D404A21

Q34031859-1715CA64-E210-4399-A964-205425927FBC

Q34031859-2106D6DD-ACED-4582-95B3-AF196724B114

Q34031859-2D6140B4-EDC4-4D17-A9DE-0A4AE678CBFA

Q34031859-31254426-A567-41C7-A854-C32562C40E96

Q34031859-39D9F507-4AAE-4876-80B3-92CE3EE1C43C

P304

Q34031859-432B161E-4969-489A-88A5-EEC7E5FF3BEC

P31

Q34031859-262067AA-2309-4A92-B76D-8984FB374F12

P356

Q34031859-9D6E9847-E24F-450D-A74D-03EAD27A0CD3

P407

Q34031859-A08F268A-DB46-4770-8761-67075D3CD06F

P433

Q34031859-7F0831FD-4866-4B56-B0F7-36FE3344E82F

P478

Q34031859-F93EB6A6-6C2A-46BB-B2B9-9022F426EC54

P577

Q34031859-A2145C38-5881-4497-91AE-44E932D9A18B

P5875

Q34031859-1DC627A4-EB2D-4FB7-A2D9-7F72A07098CF

P698

Q34031859-06BD9103-9700-44CA-AF29-68236B3076BD

P921

Q34031859-A2AD5DC7-A68C-4B81-9DD1-3600F466CC9D

Q34031859-C4E78F22-ED49-4CFF-936F-82DEC1C73D62

P932

Q34031859-63DE106B-EAB7-47DE-AF29-D99B78C87E76

P356

1078-0432.CCR-10-0005

P1433

Clinical Cancer Research

P1476

Targeted gene silencing using RGD-labeled chitosan nanoparticles.

@en

P2093

Alpa M Nick

http://www.w3.org/2001/XMLSchema#string

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Chunhua Lu

http://www.w3.org/2001/XMLSchema#string

Deyu Shen

http://www.w3.org/2001/XMLSchema#string

Edna M Mora

http://www.w3.org/2001/XMLSchema#string

Eun Ji Nam

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

Hee Dong Han

http://www.w3.org/2001/XMLSchema#string

Hye Sun Kim

http://www.w3.org/2001/XMLSchema#string

Jeong Won Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma

Nanoparticle therapeutics: an emerging treatment modality for cancer

An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment.

Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins.

RNAi therapeutics: principles, prospects and challenges.

Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity.

Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

P304

3910-3922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0005

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44664241

http://www.w3.org/2001/XMLSchema#string

P698

20538762

http://www.w3.org/2001/XMLSchema#string

P921

P932

2912984

http://www.w3.org/2001/XMLSchema#string